A Phase 2 interventional study of SPD489 20 mg and SPD489 50 mg in Sleep Deprivation, sponsored by Shire. Completed at 1 site in United States. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Sleep Deprivation with a site in United States — 30 open to participants now, 35 under way, none of them phase 3. Sleep Deprivation · United States.
Among the 146 studies in Sleep Deprivation with a site in United States, this one is the 24th largest by enrollment of the 127 interventional ones that give a count, is one of 5 that started in 2010, is one of 6 in phase 2, and was the 26th registered.
314 studies on the registry are indexed under Sleep Deprivation; 59 are open to participants now.
Browse Sleep Deprivation studies →30 of the 146 studies in Sleep Deprivation with a site in United States are open now. Recruiting first, the newest first:
Harmony Biosciences Management, Inc. · Sites in United States
Ages 18–55 · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 21–60 · Healthy volunteers
University of Arizona · Sites in United States
Ages 18–55
Children's Hospital of Philadelphia · Sites in United States
Ages 13–18
University of Utah · Sites in United States
Ages 18–35 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Sleep Deprivation studies recruiting now, 11 (26%) set no upper age limit and 28 (65%) stop at 75 or younger; 5 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 40 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 1 · Phase 4 7
First in 1999; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 50 across 259 interventional studies indexed under Sleep Deprivation.
Median enrollment 56 across the 127 interventional studies, 64 across the 19 observational. Of the 106 that completed or were terminated, 27 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 146 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 1 study filed under Sleep Deprivation — fewer than ten, so there is no comparison to draw.
7 of the studies in Sleep Deprivation with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06642246Children's Hospital of PhiladelphiaSleep Promotion and Pediatric Hypertension | 2026-11 |
| NCT06336525Brigham and Women's HospitalAdult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities. | 2027-01-31 |
| NCT05393830Beth Israel Deaconess Medical CenterThe Effect of Sleep Loss on Emotion Regulation | 2027-04-01 |
| NCT05703347Children's Hospital of PhiladelphiaOptimizing a Mobile Health Platform for Sleep Promotion and Obesity Prevention in Children | 2027-06 |
| NCT02945501U.S. Army Medical Research and Development CommandTranscranial Electrical Stimulation (TES) at Slow Oscillation (SO) Frequency During NREM Sleep | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 146 studies in Sleep Deprivation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-blind, single center, parallel group, placebo and active comparator, controlled study to characterize the wake promoting effects of single doses of SPD489 in healthy adult male undergoing acute sleep deprivation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SPD489 20 mg
Drug: SPD489 50 mg
Drug: SPD489 70 mg
Drug: Armodafinil
Drug: Placebo
Single oral dose of 20 mg
Also known as: Vyvanse
Single oral dose of 50 mg
Also known as: Vyvanse
Single oral dose of 70 mg
Also known as: Vyvanse
Single oral dose of 250 mg
Single oral dose
Maintenance of Wakefulness Test (MWT)
The MWT was conducted to determine the subjects' ability to stay awake. Subjects sat in a darkened room and were told to "stay awake as long as possible" during the 30 minute session. This is an indicator of how well you are able to function and remain alert in quiet times of inactivity. Higher times are better.
Time frame: Over a period of 8 hours
Karolinska Sleepiness Scale (KSS) Scores
The KSS is a 9-point scale on which the subject rates sleepiness from 1 (very alert) to 9 (very sleepy/fighting sleep). Lower score is better.
Time frame: Over a period of 15 hours
KSS Scores by Timepoint
The KSS is a 9-point scale on which the subject rates sleepiness from 1 (very alert) to 9 (very sleepy/fighting sleep). Lower score is better.
Time frame: Over a period of 15 hours
Psychomotor Vigilance Task (PVT) Scores
PVT assesses behavioral alertness. Subjects were required to respond to a visual stimulus by pressing a button on a mechanical device and the reaction time was measured. Higher scores indicate attention lapses.
Time frame: Over a period of 12 hours
PVT Scores by Timepoint
PVT assesses behavioral alertness. Subjects were required to respond to a visual stimulus by pressing a button on a mechanical device and the reaction time was measured. Higher scores indicate attention lapses.
Time frame: Over a period of 12 hours
| Milestone | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo |
|---|---|---|---|---|---|
| Started | 27 | 27 | 27 | 27 | 27 |
| Completed | 27 | 27 | 27 | 27 | 27 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
The MWT was conducted to determine the subjects' ability to stay awake. Subjects sat in a darkened room and were told to "stay awake as long as possible" during the 30 minute session. This is an indicator of how well you are able to function and remain alert in quiet times of inactivity. Higher times are better.
| Minutes | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo |
|---|---|---|---|---|---|
| Maintenance of Wakefulness Test (MWT) | 23.3 ± 1.10 | 27.9 ± 0.64 | 29.3 ± 0.44 | 27.6 ± 0.63 | 15.3 ± 1.00 |
The KSS is a 9-point scale on which the subject rates sleepiness from 1 (very alert) to 9 (very sleepy/fighting sleep). Lower score is better.
| Units on a scale | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo |
|---|---|---|---|---|---|
| Karolinska Sleepiness Scale (KSS) Scores | 4.7 ± 0.21 | 4.0 ± 0.21 | 3.6 ± 0.21 | 4.7 ± 0.21 | 5.2 ± 0.21 |
The KSS is a 9-point scale on which the subject rates sleepiness from 1 (very alert) to 9 (very sleepy/fighting sleep). Lower score is better.
| Units on a scale | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo |
|---|---|---|---|---|---|
| 7:50pm | 2.9 ± 0.19 | 3.0 ± 0.19 | 2.6 ± 0.19 | 2.6 ± 0.19 | 2.8 ± 0.19 |
| 8:50pm | 2.7 ± 0.20 | 2.7 ± 0.20 | 2.6 ± 0.20 | 2.7 ± 0.20 | 3.0 ± 0.20 |
| 9:50pm | 2.9 ± 0.23 | 3.1 ± 0.23 | 2.6 ± 0.23 | 3.1 ± 0.23 | 3.1 ± 0.23 |
| 10:50pm | 2.8 ± 0.26 | 3.2 ± 0.26 | 2.4 ± 0.27 | 2.9 ± 0.26 | 3.7 ± 0.27 |
| 11:50pm | 3.2 ± 0.29 | 3.1 ± 0.29 | 2.5 ± 0.29 | 3.4 ± 0.29 | 3.9 ± 0.29 |
| 12:50am | 3.6 ± 0.29 | 2.9 ± 0.29 | 2.6 ± 0.29 | 3.3 ± 0.29 | 4.5 ± 0.29 |
| 1:50am | 4.0 ± 0.31 | 3.2 ± 0.31 | 3.0 ± 0.31 | 3.8 ± 0.31 | 4.7 ± 0.31 |
| 2:50am | 4.5 ± 0.35 | 3.7 ± 0.35 | 3.5 ± 0.35 | 4.7 ± 0.35 | 5.7 ± 0.35 |
| 3:50am | 5.2 ± 0.36 | 3.9 ± 0.36 | 3.7 ± 0.36 | 5.5 ± 0.36 | 6.4 ± 0.36 |
| 4:50am | 6.1 ± 0.36 | 4.4 ± 0.36 | 4.2 ± 0.36 | 6.0 ± 0.36 | 6.6 ± 0.36 |
| 5:50am | 6.7 ± 0.37 | 5.1 ± 0.37 | 4.6 ± 0.37 | 6.3 ± 0.37 | 7.1 ± 0.37 |
| 6:50am | 6.7 ± 0.38 | 5.7 ± 0.38 | 4.8 ± 0.38 | 6.7 ± 0.38 | 7.3 ± 0.38 |
| 7:50am | 6.5 ± 0.39 | 5.5 ± 0.39 | 4.7 ± 0.39 | 6.6 ± 0.39 | 7.2 ± 0.39 |
| 8:50am | 5.9 ± 0.41 | 5.0 ± 0.41 | 4.4 ± 0.41 | 6.0 ± 0.41 | 5.4 ± 0.41 |
| 9:50am | 5.6 ± 0.38 | 4.6 ± 0.38 | 4.5 ± 0.38 | 5.7 ± 0.38 | 5.9 ± 0.38 |
| 10:50am | 6.2 ± 0.41 | 5.4 ± 0.41 | 5.0 ± 0.41 | 6.0 ± 0.41 | 6.2 ± 0.41 |
PVT assesses behavioral alertness. Subjects were required to respond to a visual stimulus by pressing a button on a mechanical device and the reaction time was measured. Higher scores indicate attention lapses.
| msec | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo |
|---|---|---|---|---|---|
| Psychomotor Vigilance Task (PVT) Scores | 243.6 ± 3.59 | 234.8 ± 3.58 | 243.5 ± 3.58 | 243.7 ± 3.59 | 270.2 ± 3.59 |
PVT assesses behavioral alertness. Subjects were required to respond to a visual stimulus by pressing a button on a mechanical device and the reaction time was measured. Higher scores indicate attention lapses.
| msec | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo |
|---|---|---|---|---|---|
| 9:15pm | 231.6 ± 3.50 | 233.2 ± 3.49 | 234.9 ± 3.49 | 235.5 ± 3.49 | 241.3 ± 3.50 |
| 11:15pm | 232.6 ± 2.98 | 230.9 ± 2.97 | 231.2 ± 2.97 | 229.3 ± 2.97 | 249.3 ± 2.98 |
| 1:15am | 231.5 ± 3.89 | 231.5 ± 3.88 | 230.2 ± 3.89 | 233.0 ± 3.88 | 256.7 ± 3.89 |
| 3:15am | 243.6 ± 4.65 | 227.4 ± 4.64 | 240.7 ± 4.64 | 242.5 ± 4.64 | 280.7 ± 4.65 |
| 5:15am | 253.4 ± 4.67 | 237.7 ± 4.66 | 242.5 ± 4.66 | 249.5 ± 4.66 | 291.6 ± 4.67 |
| 7:15am | 257.9 ± 7.67 | 242.6 ± 7.67 | 259.2 ± 7.67 | 259.1 ± 7.67 | 295.5 ± 7.67 |
| 9:15am | 254.8 ± 10.84 | 240.0 ± 10.84 | 265.9 ± 10.84 | 256.7 ± 10.93 | 276.1 ± 10.84 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPD489 20 mg | — | 0/27 (0%) | 1/27 (3.7%) |
| SPD489 50 mg | — | 0/27 (0%) | 5/27 (18.5%) |
| SPD489 70 mg | — | 0/27 (0%) | 4/27 (14.8%) |
| Armodafinil 250 mg | — | 0/27 (0%) | 3/27 (11.1%) |
| Placebo | — | 0/27 (0%) | 1/27 (3.7%) |
| Event | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/27 | 4/27 | 2/27 | 2/27 | 1/27 |
| NauseaGastrointestinal disorders | 1/27 | 1/27 | 2/27 | 1/27 | 0/27 |
| VomitingGastrointestinal disorders | 0/27 | 2/27 | 0/27 | 0/27 | 0/27 |
| Age, Continuous(years) | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 26.4 ± 5.03 | 28.7 ± 5.95 | 28.3 ± 5.04 | 27.0 ± 5.09 | 28.1 ± 6.83 | 27.7 ± 5.62 |
| Age, Customized(Participants) | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| 18 to 40 years | 27 | 27 | 27 | 27 | 27 | 135 |
| Sex: Female, Male(Participants) | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 27 | 27 | 27 | 27 | 27 | 135 |
| Region of Enrollment(Participants) | SPD489 20 mg | SPD489 50 mg | SPD489 70 mg | Armodafinil 250 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 27 | 27 | 27 | 27 | 27 | 135 |
Ran from Apr 2010 to primary completion in Jul 2010, 3 months.
Results were first posted in Jun 2011, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine